New innovations in the health-care system: Toronto-based Ventripoint Diagnostics Ltd. (TSX-Venture:VPT) got hearts beating faster Wednesday morning, with word it has submitted for regulatory approvals in Canada and other countries for its next-generation VMS+ 3.0 system.
VMS+ 3.0 system is designed to use Artificial Intelligence for volumetric measurements and ejection fractions for all four chambers of the heart, which are key indicators in cardiac diseases.
VPT claims this system to be a cost-effective diagnostic tool for measuring whole heart function utilizing standard 2D ultrasound. The system has a new patent-pending position sensor technology developed at Ventripoint to improve patient management and overall experience during the cardiac echo exam for pediatric and adult patients
Said CEO George Adams, "I am proud of the exemplary work performed by the regulatory affairs and design and development teams as we embark on this major milestone of submitting for regulatory approvals to the FDA, Health Canada and CE Notified Body for our VMS+ 3.0 system.”
Shares of VPT grabbed a penny, or 7.1%, to 15 cents, on 270,000 shares.